David Payne

David Payne serves as a key procurement lead within the W4PZ USA Medical Research Acquisition Act under the Department of the Army, overseeing the acquisition of advanced biological products critical to warfighter health and operational readiness. He manages complex research and development contracts focused on translating cutting-edge biomedical innovations into field-deployable medical solutions, including therapeutics, vaccines, and biologic countermeasures. His work directly supports the agency’s mission to bridge the gap between laboratory discovery and military medical application, ensuring rapid acquisition of novel biological products that enhance force protection and combat casualty care. Payne specializes in early-stage R&D procurements, clinical translation programs, and high-risk, high-reward biomedical contracts requiring stringent regulatory compliance and technical oversight. While specific contractor relationships are not publicly enumerated, Payne’s procurement portfolio consistently engages established biopharmaceutical manufacturers and specialized life sciences firms with proven expertise in GMP-compliant biological product development. His contracting patterns reflect collaboration with vendors possessing advanced capabilities in cell and gene therapy, recombinant protein production, and biosafety level 3/4 containment manufacturing. He prioritizes technical excellence and regulatory alignment, often requiring vendors to demonstrate FDA-pre-IND engagement, cGMP certification, and scalable manufacturing infrastructure. Payne’s acquisition strategy reflects a strict focus on full and open competition, with 100% of awards issued under no set-aside conditions. This approach underscores a mission-critical emphasis on speed, scalability, and technical capability over socioeconomic preferences, ensuring the fastest possible access to the most advanced biological solutions for the warfighter. His primary procurement focus lies within NAICS 325414—Biological Product (except Diagnostic) Manufacturing—where he sources novel therapeutics, biologics, and advanced medical countermeasures. His domain expertise centers on monoclonal antibodies, mRNA-based platforms, viral vector systems, and other next-generation biologics requiring specialized manufacturing, cold-chain logistics, and rigorous clinical validation pathways.